Special Issue

Modern Adjuvants and Their Roles in Vaccine Development

Message from the Guest Editor

Due to the uniqueness of each disease and the specific types of immune responses to be modulated, various kinds of adjuvants are needed to induce optimal immune responses against a particular disease. Vaccine adjuvants may also need to be tailored for use in different age groups due to the age-related differential immune responses to vaccines. In the past, adjuvant development has mainly relied on empirical experience, and only a few adjuvants have been approved for human use since the first(Alum) was discovered over 90 years ago. Significant advances have been made in the last three decades in understanding how adjuvants work. Modern techniques, such as high-throughput screening and in-silico screening, have also been used to discover novel adjuvants for human use. The last two decades have also seen increased investment in novel adjuvant development. These efforts are expected to accelerate novel adjuvant discovery and development. This Special Issue welcomes submissions of adjuvant discovery and development in diverse types of vaccines (e.g., subunit, mRNA-based) against infectious diseases, cancer, or immune-mediated diseases.

Guest Editor

Dr. Xinyuan Chen
Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI 02881, USA

Deadline for manuscript submissions

closed (20 February 2025)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/165811

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

MDPI